September 21, 1999

NORTHWEST BIOTHERAPEUTICS, INC. AND BATTELLE ANNOUNCE PROSTATE CANCER COLLABORATION

Northwest Biotherapeutics, Inc. and Battelle, one of the world's leading R&D organizations, announced today that they are forming a strategic collaboration to commercialize a new generation of radio-pharmaceutical technology for prostate cancer.

Northwest Biotherapeutics and Battelle plan to apply Battelle's material science,radio-pharmaceutical, and healthcare product development core competencies and Northwest Biotherapeutics' therapeutic product development and clinical trial expertise to commercialize a new approach for treating early-stage prostate cancer. The approach consists of radioactive isotopes delivered in phase-changing liquid polymers for infusion in prostate tissue rather than the use of radiation-encased in metallic implants referred to as "seeds." This innovation is expected to simplify the implantation of radiation in the prostate and should improve treatment efficacy by allowing the use of a wider range of isotopes at safe yet more effective doses of radioactivity.

The American Cancer Society projects that 179,000 new cases of prostate cancer will be diagnosed in the U.S. this year, representing 29% of all newly diagnosed cases of cancer in American men. Prostate cancer is expected to result in one male death every fourteen minutes and represents a serious health threat for one out of every five males.

"This collaboration will formalize an exciting pre-existing relationship which has already yielded promising preliminary data," said Daniel 0. Wilds, President and Chief Executive Officer, Northwest Biotherapeutics. "This is a highly energized mutual effort with the goal of introducing an important advance for the treatment of localized prostate cancer."

"Battelle's business is innovation," said Richard D. Rosen, Battelle Pharmaceutical and Medical Products, Vice President and General Manager. "Our developing relationship with Northwest Biotherapeutics is another example of our commitment to move technologies from the laboratory and into products in the commercial marketplace. We are very enthusiastic about our evolving relationship with Northwest Biotherapeutics to commercialize a new approach for prostate cancer treatment." The technology underlying this novel therapy is based on research conducted at the Pacific Northwest National Laboratory, which is managed by Battelle.

Northwest Biotherapeutics, Inc. is a Seattle, Washington, based company focused on developing and commercializing products and services to improve care for prostate and other cancer patients. In addition to its relationship with Battelle for localized prostate cancer, it is perfecting an immunotherapy-based platform technology for treating a number of life-threatening types of cancer.

Battelle focuses on technology development, product development, technology commercialization, and laboratory management. Headquartered in Columbus, Ohio, Battelle has annual revenues of nearly $1 billion and more than 60 locations throughout the world.